Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Jane Street Group LLC cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 51.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 262,248 shares of the company’s stock after selling 274,078 shares during the period. Jane Street Group LLC owned about 0.38% of Replimune Group worth $2,874,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of REPL. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $57,000. Arizona State Retirement System acquired a new position in Replimune Group during the 2nd quarter worth approximately $108,000. Quest Partners LLC lifted its stake in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Replimune Group in the third quarter valued at approximately $133,000. Institutional investors own 92.53% of the company’s stock.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on REPL. Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $17.29.

Replimune Group Trading Up 4.0 %

NASDAQ:REPL opened at $12.49 on Friday. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm’s fifty day moving average is $12.25 and its 200-day moving average is $10.73. The firm has a market cap of $854.53 million, a P/E ratio of -4.10 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Equities analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.